RayzeBio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by VIKING GLOBAL INVESTORS LP, was filed 21 Sept 2023.
RayzeBio, Inc.: what insiders have been doing
RayzeBio, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). No insider at RayzeBio, Inc. has published a filing in the past twelve months. The most recent one dates from 28 February 2024.
The full history, which starts in 2023, counts 3 purchases against no sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended September 2023 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 1,743,556 sharesCommon StockSEC:0000905148-24-000813:1
- 1,743,556 sharesCommon StockSEC:0000905148-24-000814:1
- 4,899,144 sharesCommon StockSEC:0000905148-24-000814:0
- 4,899,144 sharesCommon StockSEC:0000905148-24-000813:0
- 367,446 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005525:0
- 1,209,764 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005511:0
- 78,433 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005502:0
- 323,455 shares@ US$62.5099.5% of flowCommon StockSEC:0001415889-24-005507:0
- 1,622,968 shares@ US$62.50100.0% of flowCommon StockSEC:0001415889-24-005500:0
- 30,875 shares@ US$3.240.5% of flowCommon StockSEC:0001415889-24-002852:0
- 930,556 shares@ US$18.0067.0% of flowCommon StockSEC:0000905148-23-000959:3Canonical exit: 18 Dec 2023 (T+90)
- 458,333 shares@ US$18.0033.0% of flowCommon StockSEC:0000905148-23-000959:5Canonical exit: 18 Dec 2023 (T+90)
- 1,123,862 sharesCommon StockSEC:0000905148-23-000957:1
- 247,343 sharesCommon StockSEC:0000905148-23-000957:2
- 494,687 sharesCommon StockSEC:0000905148-23-000959:1
- 2,609,392 sharesCommon StockSEC:0000905148-23-000959:2
- 1,285,223 sharesCommon StockSEC:0000905148-23-000959:4
- 494,687 sharesCommon StockSEC:0000905148-23-000958:1
- 2,609,392 sharesCommon StockSEC:0000905148-23-000958:2
- 1,285,223 sharesCommon StockSEC:0000905148-23-000958:4
- 494,687 sharesCommon StockSEC:0001104659-23-102920:1
- 498,510 sharesCommon StockSEC:0001104659-23-102920:2
- 973,653 sharesCommon StockSEC:0001209191-23-050305:1
- 236,111 shares@ US$18.005.4% of flowCommon StockSEC:0001209191-23-050305:2Canonical exit: 18 Dec 2023 (T+90)
- 864,509 sharesCommon StockSEC:0000905148-23-000958:0
25 of 30 declarations
About RayzeBio, Inc.
RayzeBio, Inc. is a company focused on developing innovative therapies for cancer treatment. It is listed on the XNAS market.
Written on 25 June 2026 from the filings and market data available that day. Live figures are in the blocks above.
The weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.